Charles River fewer steps more sustainable endotoxin testing Get Started

« Previous article
Free Download - Acce...

28th November 2022  Product update: QIAGEN Benelux B.V.

Quick and Easy Identification of Clade I & II of Monkeypox Virus With NeuMoDx MPXV (RUO)

QIAGEN N.V. has launched the NeuMoDx MPXV Test Strip, a multiplex test that identifies both clades (variants) of monkeypox – currently for research use only (RUO). It is designed as a dual-target assay to reduce false negative results, incorrectly indicating the absence of the virus. It differentiates between the clade I and clade II variants, delivering first results in around 70 minutes on QIAGEN’s easy to use, fast and flexible NeuMoDx 96 and NeuMoDx 288 Molecular Systems.

The NeuMoDx assay extracts DNA from lesion fluid swabs to isolate the target nucleic acids and then conducts a real-time polymerase chain reaction. NeuMoDx has a simple 3-step workflow. Test strips and core reagents and consumables are ready-to-use, can remain on board for a minimum of 7 days and can be loaded whilst the system is operating. The NeuMoDx system is always ready to run and offers true random access testing capabilities, has up to 8 hours walkaway time and produces minimal waste. The system can run up to 30 different assays and offers the versatility to run IVD certified assays, self-developed tests (SDTs) and RUO assays.

QIAGEN has been working with healthcare authorities around the world since the global monkeypox outbreak began this spring to contribute its broad testing portfolio and expertise as a trusted partner in an urgent global health response. Its new assay joins a portfolio that addresses all testing needs. QIAGEN this summer launched the QIAstat-Dx Viral Vesicular Panel RUO, the world’s first syndromic test, for research use only, to differentiate between monkeypox and five other pathogens that cause similar symptoms.

QIAGEN’s sample-technology kits, testing components and instruments are also being used by public health agencies to develop their own tests. The NeuMoDx clinical PCR system can run these so-called self-developed tests (SDTs), while enabling molecular diagnostic laboratories to process ever-larger volumes and deliver ever-faster insights into monkeypox and other infectious diseases.

To learn more about the NeuMoDx MPXV Test Strip, please visit:



Date Published: 28th November 2022

Source article link: View

Note: This content has been edited by a rapidmicrobiology staff writer for style and content.

View full company details